According to Otsuka Pharmaceutical, Megakaryon will put into practical use the technology for producing platelets from iPS cells developed by Professor Hiromitsu Nakauchi of the Institute of Medical Science, the University of Tokyo, and Deputy Director Hiroyuki Eto of the Center for iPS Cell Research and Application, Kyoto University in 2011. A bio-venture company from a university that was established.

　With the declining birthrate and aging population, there are concerns about a shortage of blood products derived from blood donated blood products.Otsuka Pharmaceutical is proceeding with platelet research, such as developing the anti-blood small blood plate "Pletal", and decided that this investment would provide a synergistic effect on the research.In 2016, Otsuka Pharmaceutical Factory signed a joint research agreement with Megakaryon for a preservation solution that protects purified iPS platelets.The investment amount is 5 million yen each for both companies.

　In addition to the Otsuka Group, Megakaryon will also receive investment from the Innovation Network Corporation of Japan (Tokyo, President Mikihide Katsumata) and multiple venture capital firms.With a total investment of 37 billion yen, the company will accelerate the commercialization of platelet products by strengthening the research base for regenerative medicine and building a mass production system.

　Otsuka Pharmaceutical says, "By supporting the development of Megakaryon, we would like to contribute to strengthening Japan's international competitiveness in the field of regenerative medicine using iPS cells."